Johnson & Johnson (JNJ) (JNJ) officials hid the risks of the antipsychotic drug Risperdal to boost sales and should be held liable for misleading Arkansas doctors and patients, a lawyer said. J&J’s Janssen unit made misleading claims about Risperdal’s effectiveness in a letter to more than 6,000 Arkansas doctors and downplayed its diabetes risks on warning labels, Fletch Trammell, one of the state’s lawyers, told a jury in Little Rock today. Arkansas is seeking more than $1.25 billion in penalties over the Risperdal marketing campaign. “They hid those risks, they buried them in the label,” Trammell told jurors in closing arguments of the state’s lawsuit over the marketing campaign. Janssen officials “had a lot at stake. If Risperdal went down, the company went down, too.” It’s the fifth jury trial over states’ claims that J&J, the second-biggest (JNJ) maker of health products, hid Risperdal’s diabetes risks and tricked Medicaid regulators into paying millions of dollars more than they should have for the medicine. J&J ended the most-recent trial in Texas with a $158 million settlement in January. J&J’s lawyers countered that jurors hadn’t heard testimony from a single Arkansas resident who claimed to be harmed by the drug and state officials never warned consumers about Risperdal’s alleged health threats.